Skin rash
💎 Taxanes such as paclitaxel and docetaxel can cause hypersensitivity or infusion-related reactions.
💎 A skin rash can be an early manifestation of an allergic response to the medication or its formulation.
💎 The nurse should assess for accompanying pruritus, wheezing, dyspnea, hypotension, or facial swelling.
💎 Corticosteroids and antihistamines are often administered before treatment to reduce the risk of hypersensitivity.
💎 A rapidly developing rash requires immediate evaluation and possible interruption of the taxane infusion.
Facial flushing
💎 Facial flushing can occur during a taxane-related hypersensitivity reaction, particularly during the early portion of the infusion.
💎 The nurse should observe the client closely during administration because reactions can develop rapidly.
💎 Flushing accompanied by dyspnea, chest tightness, wheezing, or hypotension can indicate a serious infusion reaction.
💎 The medication should be stopped immediately when a severe reaction is suspected.
💎 Emergency medications and supportive equipment should remain available while taxanes are being administered.
Peripheral neuropathy
💎 Peripheral neuropathy is a common dose-related toxicity associated with taxane medications.
💎 The client may experience numbness, tingling, burning pain, or decreased sensation in the hands and feet.
💎 Progressive neuropathy can interfere with walking, balance, fine-motor activities, and the ability to perform daily tasks safely.
💎 The nurse should assess sensory and motor function before treatment and throughout the chemotherapy regimen.
💎 Severe or worsening neuropathy may require a dose reduction, treatment delay, or discontinuation of the medication.
Bradycardia
💎 Taxanes, particularly paclitaxel, can cause cardiac conduction changes, including asymptomatic bradycardia.
💎 The nurse should monitor the client’s pulse, blood pressure, and cardiovascular status during therapy.
💎 Mild bradycardia may be transient, but dizziness, syncope, hypotension, or chest discomfort requires immediate evaluation.
💎 Clients with preexisting cardiac disease or concurrent cardiotoxic medications require closer observation.
💎 Clinically significant cardiac changes should be reported promptly to the oncology provider.